Bosentan for chronic thromboembolic pulmonary hypertension.

@article{Confalonieri2009BosentanFC,
  title={Bosentan for chronic thromboembolic pulmonary hypertension.},
  author={Marco Confalonieri and Metka Kodric and Cinzia Longo and Fabio Giuseppe Vassallo},
  journal={Expert review of cardiovascular therapy},
  year={2009},
  volume={7 12},
  pages={1503-12}
}
Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe and underdiagnosed disease characterized by progressive hypertension secondary to organized thrombi in pulmonary vessels. The arteriolar lesions of CTEPH are similar to those seen in idiopathic pulmonary arterial hypertension (PAH). Surgical disobliteration of the vessels by pulmonary endarterectomy is the therapy of choice but this is not suitable for all cases. To date, there is no licensed specific drug for CTEPH. Endothelin-1… CONTINUE READING
5 Citations
47 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Hope at last? Bosentan for inoperable PAH

  • L. Nainggolan
  • Heartwire News 30December 2008 www.theheart.org…
  • 2009

Long - term safety profile of bosentan in patients with chronic thromboembolic pulmonary hypertension ( CTEPH ) : results from the TRAX database

  • J Carlsen, MM Hoeper, DG Kiely
  • 2007

Similar Papers

Loading similar papers…